Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail

por Mohamed, Mohamed‐Eslam F., Feng, Tian, Enejosa, Jeffrey V., Fisniku, Ogert, Othman, Ahmed A.
Publicado 2019

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insuf...

por Fleischmann, Roy M, Genovese, Mark C, Enejosa, Jeffrey V, Mysler, Eduardo, Bessette, Louis, Peterfy, Charles, Durez, Patrick, Ostor, Andrew, Li, Yihan, Song, In-Ho
Publicado 2019

Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program

por Peterfy, Charles G, Strand, Vibeke, Friedman, Alan, Hall, Stephen, Mysler, Eduardo, Durez, Patrick, Baraliakos, Xenofon, Enejosa, Jeffrey V, Shaw, Tim, Li, Yihan, Chen, Su, Song, In-Ho
Publicado 2021

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program

por Conaghan, Philip G., Mysler, Eduardo, Tanaka, Yoshiya, Da Silva-Tillmann, Barbara, Shaw, Tim, Liu, John, Ferguson, Ryan, Enejosa, Jeffrey V., Cohen, Stanley, Nash, Peter, Rigby, William, Burmester, Gerd
Publicado 2021

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

por Cohen, Stanley B, van Vollenhoven, Ronald F, Winthrop, Kevin L, Zerbini, Cristiano A F, Tanaka, Yoshiya, Bessette, Louis, Zhang, Ying, Khan, Nasser, Hendrickson, Barbara, Enejosa, Jeffrey V, Burmester, Gerd R
Publicado 2021